{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:44:06Z","timestamp":1793479446963,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacc.2025.02.035","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T10:03:23Z","timestamp":1747044203000},"page":"1876-1897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Target Populations for Novel Triglyceride-Lowering Therapies"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5500-686X","authenticated-orcid":false,"given":"Ask T.","family":"Nordestgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tybj\u00e6rg-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank","family":"Mansbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-0633","authenticated-orcid":false,"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.02.035_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41569-022-00676-y","article-title":"Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia","volume":"19","author":"Bor\u00e9n","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2025.02.035_bib2","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","article-title":"RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts","volume":"29","author":"Watts","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jacc.2025.02.035_bib3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jacc.2025.02.035_bib4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib5","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.02.035_bib6","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.02.035_bib7","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jacc.2025.02.035_bib9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jacc.2025.02.035_bib10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.02.035_bib11","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.02.035_bib13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: volanesorsen in FPLD; the BROADEN study","volume":"16","author":"Oral","year":"2022","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.02.035_bib14","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF-21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2022.100563","article-title":"A\u00a0randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis","volume":"5","author":"Harrison","year":"2023","journal-title":"JHEP Reports"},{"key":"10.1016\/j.jacc.2025.02.035_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.02.035_bib17","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib18","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jacc.2025.02.035_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","article-title":"Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH\/MASH and type 2 diabetes in a randomized phase 2 study","volume":"23","author":"Harrison","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.02.035_bib20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study","volume":"22","author":"Loomba","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.02.035_bib21","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.02.035_bib22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF-21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib23","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.02.035_bib24","series-title":"Tietz Textbook of Laboratory Medicine","article-title":"Lipids and lipoproteins","author":"Meeusen","year":"2021"},{"key":"10.1016\/j.jacc.2025.02.035_bib25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.02.035_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.02.035_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/eurheartj\/ehz767","article-title":"Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies","volume":"41","author":"Lawler","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.02.035_bib28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.02.035_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-2002-35403","article-title":"The complex role of triglycerides in cardiovascular disease","volume":"2","author":"Abdel-Maksoud","year":"2002","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib30","doi-asserted-by":"crossref","first-page":"E1657","DOI":"10.1210\/clinem\/dgz265","article-title":"Low high-density lipoprotein cholesterol to monitor long-term average increased triglycerides","volume":"105","author":"Langsted","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.02.035_bib31","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1161\/01.CIR.96.6.1737","article-title":"Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease","volume":"96","author":"Nordestgaard","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.02.035_bib32","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1161\/01.CIR.99.22.2901","article-title":"Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease: a meta-analysis","volume":"99","author":"Wittrup","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.02.035_bib33","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2017.0972","article-title":"Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease","volume":"317","author":"Khera","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.02.035_bib34","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.02.035_bib35","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/jama.299.21.2524","article-title":"Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease","volume":"299","author":"Frikke-Schmidt","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.02.035_bib36","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/S0735-1097(03)00407-8","article-title":"Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study","volume":"41","author":"Andersen","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.02.035_bib37","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1161\/01.CIR.101.16.1907","article-title":"Elevated HDL cholesterol is a risk factor for ischemic heart disease in White women when caused by a common mutation in the cholesteryl ester transfer protein gene","volume":"101","author":"Agerholm-Larsen","year":"2000","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacc.2025.02.035_bib38","doi-asserted-by":"crossref","first-page":"E248","DOI":"10.1210\/jc.2011-1846","article-title":"LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals","volume":"97","author":"Haase","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.02.035_bib39","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.02.035_bib40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib41","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib42","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib43","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jacc.2025.02.035_bib44","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.02.035_bib45","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2025.02.035_bib46","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.02.035_bib47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib49","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","article-title":"Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease","volume":"374","author":"Stitziel","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib50","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib52","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.ATV.11.3.569","article-title":"Quantitative studies of transfer in\u00a0vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans","volume":"11","author":"Shaikh","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.jacc.2025.02.035_bib53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","article-title":"Atherogenesis: a postprandial phenomenon","volume":"60","author":"Zilversmit","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.02.035_bib54","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2025.02.035_bib55","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jacc.2023.02.034","article-title":"Clinical trial design for triglyceride-rich lipoprotein-lowering therapies: JACC focus seminar 3\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.02.035_bib56","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non\u2013HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.02.035_bib57","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.02.035_bib58","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib59","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.jacc.2025.02.035_bib60","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","author":"Behar","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.02.035_bib62","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.02.035_bib63","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib64","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib66","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.02.035_bib67","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Pradhan","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib68","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","volume":"146","author":"Ridker","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.02.035_bib69","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","article-title":"Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacc.2025.02.035_bib70","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1093\/eurheartj\/ehab555","article-title":"A\u00a0possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs","volume":"42","author":"Doi","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.02.035_bib71","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A\u00a0null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jacc.2025.02.035_bib72","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/ATVBAHA.117.310473","article-title":"APOC3 loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk: mediation- and meta-analyses of 137 895 individuals","volume":"38","author":"Wulff","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.02.035_bib73","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib74","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/CIRCGENETICS.111.960674","article-title":"Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3","volume":"5","author":"Pisciotta","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2025.02.035_bib75","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1161\/ATVBAHA.111.238766","article-title":"Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia","volume":"32","author":"Noto","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.02.035_bib76","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cca.2011.11.020","article-title":"Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation","volume":"413","author":"Mart\u00edn-Campos","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jacc.2025.02.035_bib77","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/ng1984","article-title":"Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL","volume":"39","author":"Romeo","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2025.02.035_bib78","first-page":"70","article-title":"Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans","volume":"119","author":"Romeo","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2025.02.035_bib79","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.metabol.2008.06.016","article-title":"Variation in ANGPTL4 and risk of coronary heart disease: the Atherosclerosis Risk in Communities study","volume":"57","author":"Folsom","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2025.02.035_bib80","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1161\/ATVBAHA.108.176917","article-title":"ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk","volume":"28","author":"Talmud","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.02.035_bib81","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ng.3561","article-title":"Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease","volume":"48","author":"Helgadottir","year":"2016","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.jacc.2025.02.035_bib82","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeae035","article-title":"Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk","volume":"4","author":"Landfors","year":"2024","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.jacc.2025.02.035_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117558","article-title":"Impact of loss-of-function in angiopoietin-like 4 on the human phenome","volume":"393","author":"Gagnon","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.02.035_bib84","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fendo.2020.00474","article-title":"The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans","volume":"11","author":"Bor\u00e9n","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2025.02.035_bib85","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2021.08.051","article-title":"New therapies for lowering triglyceride-rich lipoproteins: JACC focus seminar 3\/4","volume":"78","author":"Rosenson","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.02.035_bib88","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib89","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrendo.2017.119","article-title":"Angiopoietin-like 3 in lipoprotein metabolism","volume":"13","author":"Kersten","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jacc.2025.02.035_bib90","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tem.2013.12.005","article-title":"Regulation of lipoprotein lipase by Angptl4","volume":"25","author":"Dijk","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.02.035_bib91","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib92","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jacc.2025.02.035_bib93","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib94","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"issue":"13_suppl","key":"10.1016\/j.jacc.2025.02.035_bib95","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0735-1097(24)03663-5","article-title":"Solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, reduces atherogenic lipoproteins in individuals with mixed dyslipidaemia in a durable and dosedependent manner","volume":"83","author":"Ray","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.02.035_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-37465-1","article-title":"GalNAc-lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy","volume":"14","author":"Kasiewicz","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2025.02.035_bib99","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","article-title":"A\u00a0dozen years of discovery: insights into the physiology and pharmacology of FGF-21","volume":"29","author":"Kliewer","year":"2019","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.jacc.2025.02.035_bib100","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF-21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacc.2025.02.035_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.601290","article-title":"FGF-21: An emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases","volume":"11","author":"Tillman","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2025.02.035_bib102","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/joim.12580","article-title":"Fibroblast growth factor 21 night watch: advances and uncertainties in the field","volume":"281","author":"Kharitonenkov","year":"2017","journal-title":"J\u00a0Intern Med"},{"issue":"1","key":"10.1016\/j.jacc.2025.02.035_bib103","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/cpt.3278","article-title":"Efficacy and safety of fibroblast growth factor-21 analogs for the treatment of metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis","volume":"116","author":"Jeong","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2025.02.035_bib104","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.02.035_bib105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacc.2025.02.035_bib106","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100932","article-title":"Hypertriglyceridemia and multiorgan disease among U.S. adults","volume":"3","author":"Gurevitz","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacc.2025.02.035_bib108","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.02.035_bib109","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc16-0126","article-title":"Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes","volume":"39","author":"Digenio","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.02.035_bib110","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jacc.2025.02.035_bib111","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12944-024-02297-5","article-title":"Efficacy and safety of olezarsen in lowering apolipoprotein C-III and triglycerides in healthy Japanese Americans","volume":"23","author":"Karwatowska-Prokopczuk","year":"2024","journal-title":"Lipids Health Dis"},{"issue":"12","key":"10.1016\/j.jacc.2025.02.035_bib112","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200325","article-title":"RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia","volume":"2","author":"Gaudet","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jacc.2025.02.035_bib113","doi-asserted-by":"crossref","unstructured":"Gurevitz C, Rosenson RS. Metabolic dysfunction-associated steatotic liver disease, hypertriglyceridemia and cardiovascular risk. Eur J Prev Cardiol. Published online December 4, 2024. https:\/\/doi.org\/10.1093\/eurjpc\/zwae388","DOI":"10.1093\/eurjpc\/zwae388"},{"key":"10.1016\/j.jacc.2025.02.035_bib114","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCULATIONAHA.123.065866","article-title":"ANGPTL3 deficiency and risk of hepatic steatosis","volume":"148","author":"D\u2019Erasmo","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.02.035_bib115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF-21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2025.02.035_bib116","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2025.02.035_bib117","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/2047487319871733","article-title":"Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials","volume":"27","author":"Khan","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.02.035_bib118","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13059","article-title":"Contribution of remnant cholesterol to cardiovascular risk","volume":"288","author":"Langsted","year":"2020","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib119","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.02.035_bib120","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOL.0000000000000756","article-title":"Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides","volume":"32","author":"Santos-Baez","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacc.2025.02.035_bib121","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","article-title":"Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options","volume":"119","author":"Grander","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2025.02.035_bib122","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.02.035_bib123","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.31687","article-title":"Nonalcoholic steatohepatitis: current thinking from the division of hepatology and nutrition at the Food and Drug Administration","volume":"73","author":"Anania","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.02.035_bib124","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jacl.2023.04.007","article-title":"APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia","volume":"17","author":"Prohaska","year":"2023","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.02.035_bib125","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.02.035_bib126","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jacc.2025.02.035_bib127","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-Associated steatotic liver disease: October 2024 updates to AASLD practice guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jacc.2025.02.035_bib128","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1210\/clinem\/dgab624","article-title":"LLF580, an FGF-21 analog, reduces triglycerides and hepatic fat in obese adults with modest hypertriglyceridemia","volume":"107","author":"Rader","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725059923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725059923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:58:07Z","timestamp":1779242287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725059923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":124,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0735109725059923"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.02.035","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target Populations for Novel Triglyceride-Lowering Therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}